Medication beliefs in first-line and second-line treated multiple sclerosis patients
Standard
Medication beliefs in first-line and second-line treated multiple sclerosis patients. / Pust, Gesa Elena Albertine; Untiedt, Benthe; Weierstall-Pust, Roland; Randerath, Jennifer; Barabasch, Anna; Rahn, Anne Christin; Heesen, Christoph.
In: MULT SCLER RELAT DIS, Vol. 42, 07.2020, p. 102144.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Medication beliefs in first-line and second-line treated multiple sclerosis patients
AU - Pust, Gesa Elena Albertine
AU - Untiedt, Benthe
AU - Weierstall-Pust, Roland
AU - Randerath, Jennifer
AU - Barabasch, Anna
AU - Rahn, Anne Christin
AU - Heesen, Christoph
N1 - Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - BACKGROUND: Immune treatments of multiple sclerosis (MS) can be classified in first-line and second-line approaches. While in both treatment efficacy is often not easy to assess in the short-term, treatment and illness beliefs may differ in first-line and second-line treated patients. The current study aimed to assess differential beliefs about medicine and illness perception between these groups based on the hypothesis that they are closely connected to adherence behaviour.METHODS: An online survey through the website of the German MS Society was performed investigating beliefs about immune treatments as well as the patients' illness perceptions with validated questionnaires. Demographic factors, disability and self-reported adherence rates were studied as moderator variables.RESULTS: In total, 630 patients participated. Data of 433 first-line treated and 192 second-line treated patients with MS (PwMS) were analysed. Necessity beliefs and also concerns beliefs were significantly higher in second-line treated PwMS (MANCOVA p =.001 and p =.006) and generally in patients with higher disability, while illness perception did not differ between groups. Self-assessed adherence rates were around 70% for oral treatments and injectables irrespective of first-line or second-line. Nonadherence was below 5% for infusion treatments. However, most patients reported only single omissions.CONCLUSION: The current study reveals differential behavioural attitudes between first-line versus second-line-treated PwMS. However, follow-up studies are needed to further unravel the relationship between behavioural attitudes and treatment adherence.
AB - BACKGROUND: Immune treatments of multiple sclerosis (MS) can be classified in first-line and second-line approaches. While in both treatment efficacy is often not easy to assess in the short-term, treatment and illness beliefs may differ in first-line and second-line treated patients. The current study aimed to assess differential beliefs about medicine and illness perception between these groups based on the hypothesis that they are closely connected to adherence behaviour.METHODS: An online survey through the website of the German MS Society was performed investigating beliefs about immune treatments as well as the patients' illness perceptions with validated questionnaires. Demographic factors, disability and self-reported adherence rates were studied as moderator variables.RESULTS: In total, 630 patients participated. Data of 433 first-line treated and 192 second-line treated patients with MS (PwMS) were analysed. Necessity beliefs and also concerns beliefs were significantly higher in second-line treated PwMS (MANCOVA p =.001 and p =.006) and generally in patients with higher disability, while illness perception did not differ between groups. Self-assessed adherence rates were around 70% for oral treatments and injectables irrespective of first-line or second-line. Nonadherence was below 5% for infusion treatments. However, most patients reported only single omissions.CONCLUSION: The current study reveals differential behavioural attitudes between first-line versus second-line-treated PwMS. However, follow-up studies are needed to further unravel the relationship between behavioural attitudes and treatment adherence.
U2 - 10.1016/j.msard.2020.102144
DO - 10.1016/j.msard.2020.102144
M3 - SCORING: Journal article
C2 - 32428775
VL - 42
SP - 102144
JO - MULT SCLER RELAT DIS
JF - MULT SCLER RELAT DIS
SN - 2211-0348
ER -